



ProMetic

## MILLIPORE INITIAL LICENSE AGREEMENT

**MONTREAL, QUEBEC, CANADA – October 16, 2008 – ProMetic Life Sciences Inc. (TSX:PLI) (“ProMetic”)** today advised that the Initial Licence Agreement with Millipore Corporation that was disclosed in the regulatory filing dated February 8, 2008, has been terminated.

### **Forward Looking Statements**

This document contains forward-looking statements about ProMetic’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic’s Annual Information Form for the year ended December 31, 2007, under the heading “Risk Factors”. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

###

### **For further information please contact:**

Patrick Sartore  
Corporate Secretary  
ProMetic Life Sciences Inc.  
[p.sartore@prometic.com](mailto:p.sartore@prometic.com)  
+1.514.341.2115